GDTC stock is currently bearish, trading at $2.72, down 20.8% in pre-market. The decline follows market skepticism over its collaboration with SunAct Cancer Institute, as investors weigh the risks of clinical trials and uncertain outcomes. Additionally, the stock's recent volatility and lack of immediate catalysts contribute to the negative sentiment.